BioCentury
ARTICLE | Finance

Mid-cap hot streak

Biotech winners, losers in 2Q15

July 13, 2015 7:00 AM UTC

Almost all of the biotech market cap tiers tracked by BioCentury ended the second quarter in the black. The lone exception was companies valued below $200 million, which collectively fell a median 1.2%.

Big cap biotechs added 2.8%, led by Actelion Ltd. and Gilead Sciences Inc. (see "Results by Market Cap," page 17). ...